Literature DB >> 22321988

Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches.

Martine H van Miltenburg1, Jos Jonkers.   

Abstract

Genetically engineered mouse models (GEMMs) have contributed greatly to the field of cancer research. In contrast to tumor cell transplantation models, GEMMs have the potential to capture both the cell-intrinsic and cell-extrinsic factors that drive de novo formation of autochthonous tumors and their progression toward metastatic disease. In addition, GEMMs provide experimentally tractable in vivo platforms for validating candidate cancer genes, determining therapy efficacy, and defining mechanisms of drug resistance. Studies in GEMMs of human cancer provide new insight in the molecular biology of cancer and contribute to development of novel therapeutic strategies that may ultimately lead to more cures rather than temporal remissions. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22321988     DOI: 10.1016/j.gde.2012.01.004

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  16 in total

Review 1.  Pathogenesis of pancreatic cancer: lessons from animal models.

Authors:  L Charles Murtaugh
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

Review 2.  Omics and therapy - a basis for precision medicine.

Authors:  Joseph P Garay; Joe W Gray
Journal:  Mol Oncol       Date:  2012-03-08       Impact factor: 6.603

Review 3.  MicroRNAs: master regulators of drug resistance, stemness, and metastasis.

Authors:  Umar Raza; Jitao David Zhang; Ozgür Sahin
Journal:  J Mol Med (Berl)       Date:  2014-02-09       Impact factor: 4.599

Review 4.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

5.  Somatic PIK3CA mutations as a driver of sporadic venous malformations.

Authors:  Pau Castel; F Javier Carmona; Joaquim Grego-Bessa; Michael F Berger; Agnès Viale; Kathryn V Anderson; Silvia Bague; Maurizio Scaltriti; Cristina R Antonescu; Eulàlia Baselga; José Baselga
Journal:  Sci Transl Med       Date:  2016-03-30       Impact factor: 17.956

Review 6.  Imaging preclinical tumour models: improving translational power.

Authors:  Marion de Jong; Jeroen Essers; Wytske M van Weerden
Journal:  Nat Rev Cancer       Date:  2014-06-19       Impact factor: 60.716

7.  CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.

Authors:  Julia Weber; Rupert Öllinger; Mathias Friedrich; Ursula Ehmer; Maxim Barenboim; Katja Steiger; Irina Heid; Sebastian Mueller; Roman Maresch; Thomas Engleitner; Nina Gross; Ulf Geumann; Beiyuan Fu; Angela Segler; Detian Yuan; Sebastian Lange; Alexander Strong; Jorge de la Rosa; Irene Esposito; Pentao Liu; Juan Cadiñanos; George S Vassiliou; Roland M Schmid; Günter Schneider; Kristian Unger; Fengtang Yang; Rickmer Braren; Mathias Heikenwälder; Ignacio Varela; Dieter Saur; Allan Bradley; Roland Rad
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-27       Impact factor: 11.205

8.  Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

Authors:  Linda Henneman; Martine H van Miltenburg; Ewa M Michalak; Tanya M Braumuller; Janneke E Jaspers; Anne Paulien Drenth; Renske de Korte-Grimmerink; Ewa Gogola; Karoly Szuhai; Andreas Schlicker; Rahmen Bin Ali; Colin Pritchard; Ivo J Huijbers; Anton Berns; Sven Rottenberg; Jos Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

9.  Using the GEMM-ESC strategy to study gene function in mouse models.

Authors:  Ivo J Huijbers; Jessica Del Bravo; Rahmen Bin Ali; Colin Pritchard; Tanya M Braumuller; Martine H van Miltenburg; Linda Henneman; Ewa M Michalak; Anton Berns; Jos Jonkers
Journal:  Nat Protoc       Date:  2015-10-15       Impact factor: 13.491

10.  Preventive evolutionary medicine of cancers.

Authors:  Michael E Hochberg; Frédéric Thomas; Eric Assenat; Urszula Hibner
Journal:  Evol Appl       Date:  2012-12-05       Impact factor: 5.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.